What happens to your Mounjaro maintenance dose after reaching goal weight?

The decision you're actually facing at this point

Reaching a goal weight feels like an endpoint, but it opens a set of real clinical questions: should you stay on your current dose, try stepping down to a lower strength, or consider stopping? These are not questions with one right answer. The SmPC for Mounjaro, published on the eMC, describes a titration pathway from 2.5mg upward to a maximum of 15mg, but it does not specify a 'maintenance dose once goal is reached' in the way that, say, a blood-pressure medicine might. That gap is intentional: the effective dose differs significantly between individuals.

The decision you're facing is essentially a three-way fork: continue at your current dose, reduce to a lower dose, or stop. Each path has evidence around it, and each has risks. Understanding those risks is what this page is for — so that when you sit down with your prescriber, you know exactly what to ask.

Weight management at this stage is its own discipline. A good starting point is the overview of how Mounjaro maintenance dosing works, which sets out the broader clinical framework before you reach the goal-weight conversation.

What the evidence says about stopping or reducing dose at goal weight

The clinical trial data here is worth understanding clearly. Tirzepatide works by activating GIP and GLP-1 receptors to reduce appetite, slow gastric emptying and improve metabolic signalling. Those effects are present only while the drug is active in your system. When treatment stops, hunger hormones reassert themselves, and the large-scale trials (as reviewed by NICE in TA1026) showed meaningful weight regain in a significant proportion of participants who discontinued, a pattern consistent across the GLP-1 class.

That does not mean stopping is always wrong. People with modest original BMI, strong lifestyle foundations and a genuinely stable weight may manage well on a reduced dose or, after careful clinical discussion, without medication. But the data supports treating weight as a long-term condition rather than a short course. If you are curious whether you can continue to lose weight slightly even on a holding dose, the question of whether weight loss continues on a maintenance dose is addressed separately with the trial context it deserves.

Dose reduction is different from stopping. Moving from, say, 10mg to 7.5mg may preserve most of the appetite effect while easing side effects or reducing cost. For a closer look at how the maintenance dose works specifically after you have reached your weight loss goal, including what to expect when stepping down, that page covers the clinical detail worth reading before your next prescriber conversation. Others find appetite returns within weeks and weight creeps up. There is no shortcut to knowing which group you are in except trying, with a prescriber watching the trend.

How prescribers approach the dose conversation at goal weight

A prescriber considering your dose at goal weight will typically look at several things: how stable your weight has been over the past one to three months, whether you are still experiencing side effects that argue for reduction, your original starting weight and the amount lost, and your lifestyle factors including diet and activity. They are not guessing, they are reading a clinical picture.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before anything is dispensed. A real clinician reads your update and makes a decision; it is not automated. If your goal-weight conversation is happening mid-treatment, the right moment to raise it is at that review, most people find a written message or the consultation form the easiest place to lay out exactly where they are and what they are considering.

The concept of a 'golden dose' is relevant here: many people find a specific strength that fits their biology, producing good results with manageable side effects. After goal weight, the question is whether that golden dose is still the right one or whether a step down is worth testing. Worth discussing openly rather than assuming the answer either way.

For context on how costs change if a dose reduction is agreed, the private Mounjaro treatment page sets out what a complete consultation and prescription costs through a regulated pharmacy, useful for planning if your dose is likely to change.

Practical points for managing the transition well

If your prescriber agrees to a step down, a few practical things help. Weight yourself on the same set of scales, at the same time of day, once a week rather than daily, daily fluctuation is mostly water and will mislead you. Give a new lower dose at least four to six weeks before drawing conclusions; the first fortnight after a reduction often feels different as your body adjusts, and that is not necessarily a signal to reverse course.

Protein intake matters more at this stage than during active loss. Tirzepatide tends to suppress appetite broadly; some people eating less overall drift into inadequate protein, which accelerates muscle loss alongside fat. A simple target (roughly 1.2–1.6g of protein per kilogram of body weight) is a reasonable anchor while you wait for a personalised plan from a dietitian or your prescriber.

Keep your prescriber informed of trends, not just single readings. One week of a 1kg uptick after reducing dose is not a crisis; three consecutive weeks of steady gain is information worth sharing. The longer picture of life after or during Mounjaro maintenance covers these ongoing monitoring principles in more detail.

Finally, it is worth knowing that the same clinical review process that governs active treatment continues here. Mounjaro remains a prescription-only medicine at every dose, and the same GPhC-registered pharmacy standards that apply at the start of treatment apply throughout. That continuity of oversight is, in practice, the safety net during a phase where patients are often tempted to manage things themselves.